SynthesisWorld journal of surgical oncology2025
The benefit and risk of adding immunotherapy to chemoradiotherapy as the first-line treatment for limited-stage small cell lung cancer: a meta-analysis of randomized controlled trials.
Xiang Fu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.